{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"53","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as time from initial treatment to recurrence, progression or death. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works. Progression-free survival was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula \\[Breslow NE, Day NE. Statistical methods in cancer research: volume II, the design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.\\]","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level #2 (4mg MLN9708)"}],"paramType":"NUMBER","populationDescription":"Patients received 4 mg MLN9708, 4mg pomalidomide, and 40 mg dexamethasone (RP2D).","reportingStatus":"POSTED","timeFrame":"Date of first dose of study drug to first documented disease relapse, progression or death from any cause, whichever occurs first, up to 24 months. And the median follow-up for the surviving patients is at least one year.","title":"One-Year Progression-Free Survival at the Recommend Phase II Dose (RP2D)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants (%)"}